Cardiac device therapy in patients with left ventricular dysfunction and heart failure: ‘real-world’ data on long-term outcomes (mortality, hospitalizations, days alive and out of hospital)

European Journal of Heart Failure

Volumn 18, Issue 6, 2016, Pages 693-702

  Boriani, Giuseppe ^a,b   Berti, Elena ^c   Belotti, Laura Maria Beatrice ^c   Biffi, Mauro ^a   De Palma, Rossana ^c   Malavasi, Vincenzo L ^b   Bottoni, Nicola ^d   Rossi, Luca ^e   De Maria, Elia ^f   Mantovan, Roberto ^g   Zardini, Marco ^h   Casali, Edoardo ^b   Marconi, Marco ⁱ   Bandini, Alberto ^j   Tomasi, Corrado ^k   Boggian, Giulio ^l   Barbato, Gaetano ^m   Toselli, Tiziano ⁿ   Zennaro, Mauro ^o   Sassone, Biagio ^p  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c Regional Agency for Health and Social Care   (Italy)

^d S MARIA NUOVA HOSPITAL   (Italy)

^e GUGLIELMO DA SALICETO HOSPITAL   (Italy)

^f Carpi Hospital   (Italy)

^g BUFALINI HOSPITAL   (Italy)

^h UNIVERSITY HOSPITAL OF PARMA   (Italy)

ⁱ Cardiology Division   (Italy)

^j MORGAGNI PIERANTONI HOSPITAL   (Italy)

^k SANTA MARIA DELLE CROCI HOSPITAL   (Italy)

^l Ospedale di Bentivoglio   (Italy)

^m MAGGIORE HOSPITAL   (Italy)

ⁿ UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^o Baggiovara Hospital   (Italy)

^p Cento Hospital   (Italy)

more..

Author keywords

Cardiac resynchronization therapy; Defibrillators; Epidemiology; Heart failure; Hospitalizations; Outcome

Indexed keywords

AGED; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CARDIAC RESYNCHRONIZATION THERAPY DEVICE; CHARLSON COMORBIDITY INDEX; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; COMORBIDITY; CONTROLLED STUDY; DEFIBRILLATION; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART TRANSPLANTATION; HOSPITALIZATION; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; VERY ELDERLY;

EID: 84975307972     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.509     Document Type: Article

References (41)

1. Ezekowitz JA, Rowe BH, Dryden DM, Hooton N, Vandermeer B, Spooner C, McAlister FA. Systematic review: implantable cardioverter defibrillators for adults with left ventricular systolic dysfunction. Ann Intern Med 2007;147:251–262.
2. Hai OY, Mentz RJ, Zannad F, Gasparini M, De Ferrari GM, Daubert JC, Holzmeister J, Lam CS, Pochet T, Vincent A, Linde C. Cardiac resynchronization therapy in heart failure patients with less severe left ventricular dysfunction. Eur J Heart Fail 2015;17:135–143.
3. Leyva F, Nisam S, Auricchio A. 20 years of cardiac resynchronization therapy. J Am Coll Cardiol 2014;64:1047–1058.
4. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A; Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, McDonagh T, Sechtem U, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P; ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012;14:803–869.
5. European Society of Cardiology (ESC); European Heart Rhythm Association (EHRA), Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt OA, Cleland J, Deharo JC, Delgado V, Elliott PM, Gorenek B, Israel CW, Leclercq C, Linde C, Mont L, Padeletti L, Sutton R, Vardas PE. 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Europace 2013;15:1070–1118.
6. Priori SG, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, Elliott PM, Fitzsimons D, Hatala R, Hindricks G, Kirchhof P, Kjeldsen K, Kuck KH, Hernandez-Madrid A, Nikolaou N, Norekvål TM, Spaulding C, Van Veldhuisen DJ. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Europace 2015;17:1601–1687.
7. Boriani G, Rapezzi C, Diemberger I, Gonzini L, Gorini M, Lucci D, Sinagra G, Cooke RM, Di Pasquale G, Tavazzi L, Maggioni AP. Trial-generated profiles for implantation of electrical devices in outpatients with heart failure: real-world prevalence and 1-year outcome. J Eval Clin Pract 2010;16:82–91.
8. Al-Khatib SM, Hellkamp A, Bardy GH, Hammill S, Hall WJ, Mark DB, Anstrom KJ, Curtis J, Al-Khalidi H, Curtis LH, Heidenreich P, Peterson ED, Sanders G. Survival of patients receiving a primary prevention implantable cardioverter-defibrillator in clinical practice vs clinical trials. JAMA 2013;309:55–62.
9. Boriani G, Berti E, Biffi M, Marino M, Sassone B, Villani GQ, Bottoni N, Malavasi VL, Melandri F, Barbato G, Talamonti E, Marconi M; RERAI (Registry of Emilia Romagna on Arrhythmia Interventions) Investigators. Implantable electrical devices for prevention of sudden cardiac death: data on implant rates from a ‘real world’ regional registry. Europace 2010;12:1224–1230.
10. Boriani G, Berti E, Belotti LM, Biffi M, Carboni A, Bandini A, Casali E, Tomasi C, Toselli T, Baraldi P, Bottoni N, Barbato G, Sassone B; RERAI (Registry of Emilia Romagna on Arrhythmia Interventions) Investigators. Cardiac resynchronization therapy: implant rates, temporal trends and relationships with heart failure epidemiology. J Cardiovasc Med (Hagerstown) 2014;15:147–154.
11. Ariti CA, Cleland JG, Pocock SJ, Pfeffer MA, Swedberg K, Granger CB, McMurray JJ, Michelson EL, Ostergren J, Yusuf S. Days alive and out of hospital and the patient journey in patients with heart failure: insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program. Am Heart J 2011;162:900–906.
12. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40: 373–383.
13. Cowie MR, Marshall D, Drummond M, Ferko N, Maschio M, Ekman M, de Roy L, Heidbuchel H, Verboven Y, Braunschweig F, Linde C, Boriani G. Lifetime cost-effectiveness of prophylactic implantation of a cardioverter defibrillator in patients with reduced left ventricular systolic function: results of Markov modelling in a European population. Europace 2009;11:716–726.
14. Boriani G, Biffi M, Martignani C, Diemberger I, Valzania C, Bertini M, Branzi A. Expenditure and value for money: the challenge of implantable cardioverter defibrillators. QJM 2009;102:349–356.
15. Boriani G, Diemberger I, Biffi M, Martignani C. Cost-effectiveness of cardiac resynchronisation therapy. Heart 2012;98:1828–1836.
16. Gitt AK, Bueno H, Danchin N, Fox K, Hochadel M, Kearney P, Maggioni AP, Opolski G, Seabra-Gomes R, Weidinger F. The role of cardiac registries in evidence-based medicine. Eur Heart J 2010;31:525–529.
17. Bogale N, Priori S, Cleland JG, Brugada J, Linde C, Auricchio A, van Veldhuisen DJ, Limbourg T, Gitt A, Gras D, Stellbrink C, Gasparini M, Metra M, Derumeaux G, Gadler F, Buga L, Dickstein K; Scientific Committee, National Coordinators, and Investigators. The European CRT Survey: 1 year (9–15 months) follow-up results. Eur J Heart Fail 2012;14:61–73.
18. Masoudi FA, Mi X, Curtis LH, Peterson PN, Curtis JP, Fonarow GC, Hammill SC, Heidenreich PA, Al-Khatib SM, Piccini JP, Qualls LG, Hernandez AF. Comparative effectiveness of cardiac resynchronization therapy with an implantable cardioverter-defibrillator versus defibrillator therapy alone: a cohort study. Ann Intern Med 2014;160:603–611.
19. Ajijola OA, Macklin EA, Moore SA, McCarty D, Bischoff KE, Heist EK, Picard M, Ruskin JN, Dec GW, Singh JP. Inpatient vs. elective outpatient cardiac resynchronization therapy device implantation and long-term clinical outcome. Europace 2010;12:1745–1749.
20. Chen CY, Stevenson LW, Stewart GC, Bhatt DL, Desai M, Seeger JD, Williams L, Jalbert JJ, Setoguchi S. Real world effectiveness of primary implantable cardioverter defibrillators implanted during hospital admissions for exacerbation of heart failure or other acute co-morbidities: cohort study of older patients with heart failure. BMJ 2015;351:h3529.
21. Zannad F, Garcia AA, Anker SD, Armstrong PW, Calvo G, Cleland JG, Cohn JN, Dickstein K, Domanski MJ, Ekman I, Filippatos GS, Gheorghiade M, Hernandez AF, Jaarsma T, Koglin J, Konstam M, Kupfer S, Maggioni AP, Mebazaa A, Metra M, Nowack C, Pieske B, Piña IL, Pocock SJ, Ponikowski P, Rosano G, Ruilope LM, Ruschitzka F, Severin T, Solomon S, Stein K, Stockbridge NL, Stough WG, Swedberg K, Tavazzi L, Voors AA, Wasserman SM, Woehrle H, Zalewski A, McMurray JJ. Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. Eur J Heart Fail 2013;15:1082–1094.
22. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L; Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005;352:1539–1549.
23. McAlister FA, Ezekowitz JA, Wiebe N, Rowe B, Spooner C, Crumley E, Hartling L, Klassen T, Abraham W. Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: a systematic review. JAMA 2007;297:2502–2514.
24. Al-Majed NS, McAlister FA, Bakal JA, Ezekowitz JA. Meta-analysis: cardiac resynchronization therapy for patients with less symptomatic heart failure. Ann Intern Med 2011;154:401–412.
25. Boriani G, Maniadakis N, Auricchio A, Müller-Riemenschneider F, Fattore G, Leyva F, Mantovani L, Siebert M, Willich SN, Vardas P, Kirchhof P. Health technology assessment in interventional electrophysiology and device therapy: a position paper of the European Heart Rhythm Association. Eur Heart J 2013;34:1869–1874.
26. Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, Nodari S, Lam CS, Sato N, Shah AN, Gheorghiade M. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol 2014;63:1123–1133.
27. The ESCAPE Investigators and ESCAPE Study Coordinators. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE Trial. JAMA 2005;294:1625–1633.
28. Di Tano G, De Maria R, Gonzini L, Aspromonte N, Di Lenarda A, Feola M, Marini M, Milli M, Misuraca G, Mortara A, Oliva F, Pulignano G, Russo G, Senni M, Tavazzi L; IN-HF Outcome Investigators. The 30-day metric in acute heart failure revisited: data from IN-HF Outcome, an Italian nationwide cardiology registry. Eur J Heart Fail 2015;17:1032–1041.
29. Boriani G, Diemberger I, Martignani C, Biffi M, Valzania C, Bertini M, Domenichini G, Saporito D, Ziacchi M, Branzi A. Telecardiology and remote monitoring of implanted electrical devices: the potential for fresh clinical care perspectives. J Gen Intern Med 2008;23(Suppl 1):73–77.
30. Varma N, Ricci RP. Telemedicine and cardiac implants: what is the benefit? Eur Heart J 2013;34:1885–1895.
31. Boriani G. Remote monitoring of cardiac implantable electrical devices in Europe: quo vadis? Europace 2015;17:674–676.
32. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613–619.
33. Saczynski JS, Andrade SE, Harrold LR, Tjia J, Cutrona SL, Dodd KS, Goldberg RJ, Gurwitz JH. A systematic review of validated methods for identifying heart failure using administrative data. Pharmacoepidemiol Drug Saf 2012;21(Suppl 1):129–140.
34. Ghislandi S, Torbica A, Boriani G. Assessing the outcomes of implantable cardioverter defibrillator treatment in a real world setting: results from hospital record data. BMC Health Serv Res 2013;13:100.
35. McCormick N, Lacaille D, Bhole V, Avina-Zubieta JA. Validity of heart failure diagnoses in administrative databases: a systematic review and meta-analysis. PLoS One 2014;9:e104519.
36. Cipriani M, Landolina M, Oliva F, Ghio S, Vargiu S, Rordorf R, Raineri C, Ammirati E, Petracci B, Campo C, Bisetti S, Lunati M. Women with nonischemic cardiomyopathy have a favorable prognosis and a better left ventricular remodeling than men after cardiac resynchronization therapy. J Cardiovasc Med (Hagerstown). 2016;17:291–298.
37. Arshad A, Moss AJ, Foster E, Padeletti L, Barsheshet A, Goldenberg I, Greenberg H, Hall WJ, McNitt S, Zareba W, Solomon S, Steinberg JS; MADIT-CRT Executive Committee. Cardiac resynchronization therapy is more effective in women than in men: the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy) trial. J Am Coll Cardiol 2011;57:813–820.
38. Cheng YJ, Zhang J, Li WJ, Lin XX, Zeng WT, Tang K, Tang AL, He JG, Xu Q, MeiMY, Zheng DD, Dong YG, Ma H, Wu SH. More favorable response to cardiac resynchronization therapy in women than in men. Circ Arrhythm Electrophysiol 2014;7:807–815.
39. Theuns DA, Schaer BA, Soliman OI, Altmann D, Sticherling C, Geleijnse ML, Osswald S, Jordaens L. The prognosis of implantable defibrillator patients treated with cardiac resynchronization therapy: comorbidity burden as predictor of mortality. Europace 2011;13:62–69.
40. Bhavnani SP, Coleman CI, Guertin D, Yarlagadda RK, Clyne CA, Kluger J. Evaluation of the Charlson comorbidity index to predict early mortality in implantable cardioverter defibrillator patients. Ann Noninvasive Electrocardiol 2013;18:379–388.
41. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]. Eur Heart J 2006;27:1928–1932.